<DOC>
	<DOC>NCT00206648</DOC>
	<brief_summary>The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.</brief_summary>
	<brief_title>An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>RRMS patients that are receiving treatment with Avonex 30 Âµg once weekly Primary Progressive or Secondary Progressive MS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>